These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8284708)

  • 1. Hormonal therapy for metastatic prostate cancer: issues of timing and total androgen ablation.
    Cookson MS; Sarosdy MF
    South Med J; 1994 Jan; 87(1):1-6. PubMed ID: 8284708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal therapy for advanced prostatic carcinoma.
    Seftel AD; Spirnak JP; Resnick MI
    J Surg Oncol Suppl; 1989; 1():14-20. PubMed ID: 2669792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormonal therapy for locally advanced prostate cancer.
    Einstein AB
    NCI Monogr; 1988; (7):171-4. PubMed ID: 3050536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer.
    Scherr DS; Pitts WR
    J Urol; 2003 Nov; 170(5):1703-8. PubMed ID: 14532759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormonal therapy: historical perspective to future directions.
    Mcleod DG
    Urology; 2003 Feb; 61(2 Suppl 1):3-7. PubMed ID: 12667881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal therapy for stage D cancer of the prostate.
    Gudziak MR; Smith AY
    West J Med; 1994 Apr; 160(4):351-9. PubMed ID: 8023485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 10. Hormonal management of advanced adenocarcinoma of the prostate.
    Miles BJ
    Henry Ford Hosp Med J; 1989; 37(1):16-8. PubMed ID: 2670839
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
    Bayoumi AM; Brown AD; Garber AM
    J Natl Cancer Inst; 2000 Nov; 92(21):1731-9. PubMed ID: 11058616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone therapy of prostatic bone metastases.
    Huben RP
    Adv Exp Med Biol; 1992; 324():305-16. PubMed ID: 1492625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal ablation therapy for metastatic prostatic carcinoma: a review.
    Leewansangtong S; Soontrapa S
    J Med Assoc Thai; 1999 Feb; 82(2):192-205. PubMed ID: 10087729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies surrounding androgen deprivation for prostate cancer.
    Patterson SG; Balducci L; Pow-Sang JM
    Cancer Control; 2002; 9(4):315-25. PubMed ID: 12228757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A critical review of the concept of total androgen ablation in the treatment of prostate cancer.
    Schulze H; Isaacs JT; Coffey DS
    Prog Clin Biol Res; 1987; 243A():1-19. PubMed ID: 3309968
    [No Abstract]   [Full Text] [Related]  

  • 16. Medical versus surgical androgen suppression therapy for prostate cancer: a 10-year longitudinal cost study.
    Mariani AJ; Glover M; Arita S
    J Urol; 2001 Jan; 165(1):104-7. PubMed ID: 11125375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of current status of total androgen deprivation in metastasized prostate cancer.
    Debruyne FM; Witjes WP
    Eur Urol; 1993; 24 Suppl 2():67-71. PubMed ID: 8262129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy for prostate cancer: current status and future prospects.
    Miyamoto H; Messing EM; Chang C
    Prostate; 2004 Dec; 61(4):332-53. PubMed ID: 15389811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in hormonal therapy for advanced prostate cancer.
    Oottamasathien S; Crawford ED
    Oncology (Williston Park); 2003 Aug; 17(8):1047-52; discussion 1054-8. PubMed ID: 12966672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.